NASDAQ:STSA Satsuma Pharmaceuticals (STSA) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free STSA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.01▼$1.1450-Day Range$1.04▼$1.1152-Week Range$0.59▼$8.08Volume1.83 million shsAverage Volume701,788 shsMarket Capitalization$36.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Satsuma Pharmaceuticals alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Satsuma Pharmaceuticals Stock (NASDAQ:STSA)Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. STSA Stock News HeadlinesAugust 30, 2023 | usnews.comSatsuma City High SchoolJune 9, 2023 | bizjournals.comJapanese pharma acquires its crash-strapped Durham spin-outApril 25, 2024 | Schaeffer’s Research (Ad)Just Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.June 8, 2023 | bizjournals.comJapanese pharma acquires its Durham spin-outMay 18, 2023 | finance.yahoo.comSatsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of MigraineMay 3, 2023 | marketwatch.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TESS, STSA, CHRAMay 1, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Satsuma Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Shin NipponApril 25, 2023 | marketwatch.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NATI, RXDX, STSA, CHRAApril 25, 2024 | Schaeffer’s Research (Ad)Just Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.April 22, 2023 | seekingalpha.comSTSA Satsuma Pharmaceuticals, Inc.April 21, 2023 | finance.yahoo.comSatsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual MeetingApril 19, 2023 | msn.comAfter Satsuma Pharma Rockets 65% on SNBL Bid, There Could Still Be 6X More UpsideApril 18, 2023 | marketwatch.comSatsuma Pharmaceuticals Shares Soar on Shin Nippon Biomedical Deal >STSAApril 17, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Satsuma Pharmaceuticals, Inc. BuyoutApril 17, 2023 | bizjournals.comPeninsula company bets big part of potential $221M sale on future of migraine drugApril 17, 2023 | markets.businessinsider.comSatsuma Pharma Agrees To Be Acquired By Shin Nippon BiomedicalApril 17, 2023 | msn.comSatsuma Skyrockets after Acquisition by Shin NipponApril 17, 2023 | investorplace.comWhy Is Satsuma Pharmaceuticals (STSA) Stock Up 144% Today?April 16, 2023 | finance.yahoo.comSNBL to Acquire Satsuma PharmaceuticalsMarch 30, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Satsuma Pharmaceuticals (STSA)March 30, 2023 | finance.yahoo.comWe're A Little Worried About Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn RateMarch 29, 2023 | bizjournals.comMigraine drug maker seeks FDA approval and a partner as it cuts jobsMarch 28, 2023 | finance.yahoo.comSatsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business HighlightsFebruary 18, 2023 | marketwatch.com8-K: Satsuma Pharmaceuticals, Inc.February 7, 2023 | reuters.comSTSA.OFebruary 2, 2023 | finance.yahoo.comSatsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma ConferenceDecember 28, 2022 | finance.yahoo.comDespite Trial Failure, Satsuma Pharma Says Its Migraine Candidate Has Potential For ApprovalSee More Headlines Receive STSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Satsuma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryRegional Banks Current SymbolNASDAQ:STSA CUSIP85931930 CIK891106 Webwww.satsumarx.com Phone650-410-3200FaxN/AEmployees21Year Founded2016Profitability EPS (Most Recent Fiscal Year)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-115.24% Return on Assets-102.26% Debt Debt-to-Equity RatioN/A Current Ratio7.44 Quick Ratio7.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book0.78Miscellaneous Outstanding Shares33,150,000Free Float22,809,000Market Cap$36.47 million OptionableNot Optionable Beta0.10 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. John A. Kollins MBA (Age 59)Pres, CEO & Director Comp: $830kMr. Thomas P. O'Neil (Age 57)Chief Financial Officer Comp: $550.08kDr. Detlef F. Albrecht (Age 61)Chief Medical Officer Comp: $625.97kMr. Mic Iwashima (Age 44)VP & Head of Operations Mr. Robert Schultz (Age 58)Sr. VP & Head of Chemistry, Manufacturing and Controls Dr. Shannon Strom Ph.D. (Age 46)VP & Head of Regulatory Affairs Mr. Robert M. JanoskyChief Commercial OfficerMore ExecutivesKey CompetitorsXilio TherapeuticsNASDAQ:XLOBriaCell TherapeuticsNASDAQ:BCTXUnicycive TherapeuticsNASDAQ:UNCYFortress BiotechNASDAQ:FBIOOcuphire PharmaNASDAQ:OCUPView All CompetitorsInsidersKen TakanashiBought 22,053,581 shares on 6/6/2023Total: $20.07 M ($0.91/share) STSA Stock Analysis - Frequently Asked Questions How were Satsuma Pharmaceuticals' earnings last quarter? Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) released its quarterly earnings results on Tuesday, November, 9th. The financial services provider reported ($0.42) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09. What other stocks do shareholders of Satsuma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include Verrica Pharmaceuticals (VRCA), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Dynavax Technologies (DVAX), Homology Medicines (FIXX), Gilead Sciences (GILD), Novan (NOVN), Pfizer (PFE) and Akebia Therapeutics (AKBA). When did Satsuma Pharmaceuticals IPO? Satsuma Pharmaceuticals (STSA) raised $75 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore acted as the underwriters for the IPO. This page (NASDAQ:STSA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPrepare for a recession unlike any otherAmerican Hartford Gold GroupWill this $2 AI stock double overnight?Behind the MarketsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Satsuma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.